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ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of acute
respiratory coronavirus disease 2019 (COVID-19), a disease that erupted into a global pandemic
in March of 2020.2 Recently, a genome wide CRISPR screen was performed on SARS-lineage
coronaviruses and two additional recombinant viruses; the screen revealed host genes essential to
coronavirus pathogenesis and entry.7 The screen identified KDM6A, a histone demethylase, as
an important pro-viral gene.7 Building upon this observation, in this thesis, I explore the role of
Kdm6a in murine hepatitis virus (MHV), a type of mouse coronavirus. MHV is the prototypical
model for studying SARS-CoV-2 pathogenesis due to the ease of biological safety protocols and
its ability to help us characterize coronaviruses generally.41 The Kdm6a gene encodes enzyme
lysine specific demethylase 6A that is found in many cells of the body.8 Kdm6a functions as a
histone demethylase, which helps increase activity of certain genes, specifically developmental
genes.8 Though much is not known about Kdm6a’s implication in coronavirus infection,
preliminary data suggests that Kdm6a is essential to MHV-A59 and MHV-3 infection. In our
first aim, we performed RT-qPCR to elucidate Kdm6a’s role in viral entry. We found Kdm6a
knockout results in reduced Ceacam1 expression, the receptor for MHV. For our second aim, we
designed mutated Kdm6a constructs to assess which domains of Kdm6a are important in viral
infection. We proceeded to run rescue assays to observe expression of Kdm6a in Kdm6a
deficient cells. Though we did not observe expression, there are likely explanations as to why
these experiments did not work. To this end, the present study suggests that Kdm6a is important
in viral entry, possibly through regulation of receptor expression, but which of its domains are
responsible remains to be elucidated.
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INTRODUCTION
In December of 2019, the emergence of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) was reported in Wuhan, Hubei Province, China.1 By March 2020, SARS-CoV-2,
the pathogen responsible for coronavirus disease 2019 (Covid-19), sparked a global pandemic
resulting in 111 million cases and 2.46 million deaths.2 Given the virus’s devastating effects, it is
crucial we understand the biological consequences of COVID-19 for the development of
effective therapeutics and to better understand its impact on public health interventions and
implications for future zoonotic diseases.
Coronaviruses (CoVs), in the family Coronaviridae, are a group of enveloped positivesense RNA viruses named for the crownlike spikes on their surface.4 Coronaviruses are divided
into four groups: alpha, beta, gamma, and delta.10 Alpha and beta coronaviruses commonly infect
mammals, while gamma and delta coronaviruses infect birds.11 Human endemic coronaviruses,
such as the alpha human coronavirus (HCoV)-299E, alpha HCoV-NL63, beta HCoV-OC43, and
beta HCoV-HKU1 are characteristic of the common cold and cause mild upper-respiratory tract
illness.5 The more notable beta coronaviruses, Severe Acute Respiratory Syndrome Coronavirus
(SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and SARS-CoV2, are highly pathogenic and cause life-threatening respiratory tract infections in individuals.5
Though the aforementioned examples are coronaviruses that infect humans, there are beta
coronaviruses that infect model organisms, including mice. Mouse hepatitis virus (MHV) is a
beta coronavirus that solely infects the mouse species and causes pathological inflammation
resulting in hepatitis, anemia, pneumonia, and necrotizing encephalitis.41 Studying beta
coronaviruses in different host species not only allows us to understand the biology taking place
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in that specific organism, but may also shed light on the biology of coronaviruses more
generally.
Overall, coronaviruses share similar structural properties and lifecycle processes. In order
for the virus to enter the host cell, the spike (S) protein binds to cellular entry receptors on the
cell surface.21 Following viral attachment, the virus is carried into the cell via endosomes and
later fuses with viral and lysosomal membranes.21 Viral genomic RNA is released into the
cytoplasm and the genomic RNA undergoes translation and replication.21 As a result, virions are
assembled and transported out of the cell via exocytosis.4 The new viruses spread to adjacent
uninfected cells and the cycle continues.21
Given the scientific urgency to biologically understand which genes are implicated in
coronavirus infection and where in the life cycle they are acting, our lab conducted a genome
wide CRISPR screen.7 The screen included SARS-CoV-2, MERS-CoV, SARS-CoV-1 spike
complexed with Pipistrellus bat coronavirus (HKU5), and replication-competent vesicular
stomatitis virus (rcVSV) expressing the SARS-CoV-2 spike.7 The initial attachment of the virion
to the receptor by the spike gene is a key first step in viral entry and infectivity.4 Thus,
incorporating the recombinant virus expressing the spike gene of interest (rcVSV-SARS-CoV-2S) reveals which genes are acting at viral entry.7 Using different coronaviruses, in addition to
SARS-CoV-2, revealed genes conserved across CoVs.7 One gene in particular, lysine
demethylase 6a (KDM6A), scored as a top pro-viral gene in all four screens. Because it also
appeared as a hit in the rcVSV-SARS-CoV-2-S screen, this suggests KDM6A acts at viral entry.7
KDM6A encodes enzyme lysine-specific demethylase 6A, which acts to remove methyl
groups from lysine position 27 of histone 3 (H3K27).22 In the nucleus, DNA and proteins are
tightly coiled to form a complex called chromatin.42 More specifically, DNA curls itself around
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histones, creating repeating structural units known as nucleosomes.42 There are five major types
of histones: H1/H5, H2A, H2B, H3, and H4.42 All five families participate in histone
modification, with Histone H3 greatly interacting with gene promoters to DNA transcriptional
activity.42 During post-translational modification, there are several ways in which a histone can
be modified to make DNA more or less accessible. For example, histone demethylation involves
removing methyl groups that weaken chemical attractions between histone tails and DNA.26
Consequently, this makes the DNA more accessible to RNA polymerase, which in turn, results in
an increase of transcriptional activity.26 Given the critical role demethylases play in gene
regulation, it is not unexpected KDM6A has a widespread role in different tissues and contexts.26
KDM6A is made up of two main domains: the tetratricopeptide repeat domain (TPR) and
the Jumonji C domain (JmjC).22 The TPR domain associates with other methyltransferases
(KMT2C and KMT2D), which is important for chromatin enhancer activation.22 Chromatin
enhancers are short regions of DNA where proteins bind, in turn increasing the likelihood
transcription will occur.43 Enhancer activity is subdued in the presence of H3K27, but stimulated
when demethylases, like KDM6A, act at enhancer regions.44 The JmjC domain is the
catalytically active portion of the gene that is responsible for demethylase activity.22 Many
demethylases contain a catalytic JmjC domain.22 JmjC domains are a family of proteins that are
identified for their ability to modulate gene expression and associate with different histone
marks.45 The TPR and JmjC domains are important structural components of KDM6A that
remain to be interrogated to understand its effect on viral infection.
Before its involvement in coronaviruses, KDM6A was studied in a number of other viral
infections, including human papillomavirus (HPV) and respiratory syncytial virus (RSV)12. In
these viral infections, KDM6A is recruited to remove repressive trimethyl marks on H3K27 from
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the promoters of several genes, inducing pro-inflammatory responses and epigenetic
reprogramming.12 Current literature demonstrates histone demethylases are implicated in postentry processes of these DNA viruses, a phase of the viral life cycle that occurs when the viral
genome has passed through the plasma membrane and into the cytoplasm.27,28 Once the viral
genome enters the host cell, histones are swiftly loaded onto the genetic material, and viral
replication is halted.28 In order to remove these repressive marks, the virus co-opts the host’s
proteins to recruit lysine-specific demethylases.28 Though DNA viruses cannot be directly
compared to the post-entry processes of MHV or other coronaviruses, prior work from our lab
and others have revealed histone modifying enzymes to be important in the life cycle of DNA
and RNA viruses alike.7,27,28 Furthermore, KDM6A’s characterization as a pro-viral gene in
SARS-lineage CoVs and MERS prompted us to investigate Kdm6a’s role in MHV.7
MHV is a highly contagious coronavirus that affects the mouse population.23 There are
approximately 25 strains of MHV, many of them differing in organotropism, transmission, and
clinical disease.13 Out of all the strains, MHV-3, MHV-A59, and MHV-JHM are the most well
studied mouse coronaviruses. These particular strains are polytropic, meaning they affect more
than one organ in the host species.41 MHV-3 and MHV-A59 strains are virulent strains that cause
mild encephalitis and disease in the upper respiratory tract.41,47 Suggestive in its name, MHVA59 also causes hepatitis, or inflammation of the liver.41 While MHV-A59 and MHV-JHM both
replicate in the CNS, MHV-JHM is a neurovirulent strain that mainly causes acute encephalitis
and chronic demyelination.47
For MHV to enter the host cell, it initially binds to the surface receptor cell-adhesion
molecule 1 in the carcinoembryonic antigen family (CEACAM1).41 In mice, there are two allelic
variations of CEACAM1: CEACAM1a and CEACAM1b. 17 Ceacam1a has four different
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isoforms through alternative mRNA splicing. All four isoforms vary in the number of amino
acids and immunoglobulin G domains. Ceacam1b is the allelic form that is expressed in inbred
mice noted for their high incidence of sarcoma.17 CEACAM1a serves as the principal receptor
for many mouse coronaviruses, particularly MHV-A59.16,47 Other data suggests this is not the
case for MHV-JHM. As to how MHV-JHM can spread independently of its receptor is unclear,
for other strains, CEACAM1a still plays a large role in regulating viral entry.
MHV is a widely used animal coronavirus that has served as a good biological model for
SARS-CoV-1, and is now being used to mechanistically understand SARS-CoV-2.41 There are
many advantages in using MHV as a surrogate to SARS-CoV-2. First, handling MHV only
requires biosafety level 2 containment while SARS-CoV-2 requires biosafety level 3
containment.41 Second, unlike human CoVs, MHV can be studied within its natural host
species.41 Third, mice infected with particular MHV strains have similar pulmonary and
neurological responses to humans infected with SARS-CoV-2.41 When mice are intranasally
inoculated with MHV-A59 and MHV-1, lung pathology in mice post-infection is similar to lung
pathology in humans infected with SARS-CoVs and MERS-CoV.41 Additionally, recent studies
have found SARS-CoV-2 is capable of causing disease in the central nervous system (CNS).
MHV-JHM can be used as a model to elucidate viral entry into the CNS.41 Overall, MHV can be
used to study broad regulators of coronavirus infection or replication.
It is worth noting that while mouse models are easily accessible, it is not a perfect
prototype, as viral replication, clinical symptoms, and pathogenesis vary from mice to humans.
One key limitation associated with using MHV as a model to study SARS-CoV-2 are differences
in transmission route and pathogenesis. SARS-CoV-2 is transmitted via respiratory droplets of
an infected person or touching of the eyes or mouth when in contact with contaminated
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surfaces.15 In contrast, MHV usually spreads by the fecal-oral route between mice and does not
cause respiratory disease during normal transmission.23 However, it can cause respiratory disease
when introduced by other mechanisms, such as intranasal inoculation .23 Another difference is
the viral receptor in MHV and SARS-CoV-2. MHV’s viral receptor is CEACAM1a and SARSCoV-2’s viral receptor is angiotensin-converting enzyme 2 (ACE2).41 Interactions with different
receptors play a role in viral entry, tissue tropism, and viral pathogenesis that cannot be directly
translated from a mouse model to a human model. Despite these differences, understanding the
viral pathogenicity of MHV can lend insight into SARS-CoV-2 viral processes and
coronaviruses in general.
To examine KDM6A’s potentially broad role in coronavirus infection, Kdm6a KO clones
were created in a wild-type (WT) BV-2 cell line. BV-2 cells are immortalized, mouse microglial
cells that are found in the CNS.46 They are macrophage-like cells that are susceptible to MHV
infection. A previous member of the lab infected BV-2 WT and KO cells with MHV-A59 and
MHV-3 and found there was a significant decrease in viral infection in the BV-2 KO cells.
MHV-A59 and MHV-3 were chosen because they are the prototypical strains of mouse
coronavirus.23 This is evidence that Kdm6a is not only important in SARS-lineage viruses and
MERS-CoV, but also important across other coronavirus species (Figure 1).
To this end, the objectives of my thesis are to investigate Kdm6a’s role in MHV infection
and viral entry and dissect which domains are important towards this process through mutational
analysis.
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Figure 1. KDM6A is essential for MHV-A59 and MHV-3 infection.
BV-2 WT KDM6A and BV-2 KO KDM6A cells were infected with MHV-A59 and
MHV-3. Through plaque assay on L2 cells, viral production was observed 48 hours
post infection. The data demonstrates cells in the absence of KDM6A are resistant to
infection, while those with KDM6A are susceptible to MHV-A59 and MHV-3.

MATERIALS AND METHODS
Cell culture
BV-2 WT Kdm6a and single cell-derived knockout clones of Kdm6a (KO) were gifted by the
Orchard lab, located at UT Southwestern Medical Center. The WT and KO cell lines were
seeded on 10 cm plates at a density of 2.0x105 cells/plate and incubated in 5% CO2 at 37°C. BV2s were maintained and cultured in 8 mL of Gibco Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum, 1% of 100x penicillin-Streptomycinglutamine, and 1% HEPES (Thermo Fisher Scientific).
Lentiviral packaging and transduction
293T cells were incubated ~20 hours in 5% CO2 at 37°C. The next day, a mixture of three
transfection plasmids were prepared: psPAX2 packaging plasmid (12259, Addgene), vesicular
stomatitis virus with glycoprotein (VSV-G) envelope protein (8454, Addgene), and Kdm6a
lentiviral vector. Two types of Kdm6a lentiviral vectors were used: pLenti-CMV-MSC-EF112

PURO (LV101, ALSTEM) and a MSCVmu promoter based pCDH-MSC-T2A-Puro expression
vector (CD522A-1, SBI). Transient transfection was performed by combining 100 ul of OptiMEM 1 Reduced Serum Media with 6 ul TransIt (Thermo Fisher Scientific, Mirus). Next, the
mixture was incubated for 30 minutes at room temperature and added dropwise to each well in a
6-well plate. After 48 hours, the lentiviral supernatant was collected. To infect cells with the
collected lentivirus, BV-2 KO cells were placed in a 6-well plate at a density of 5e5 cells/well the
day before infection. 1 mL of lentivirus was added to each well in the presence of 1 mL DMEM.
Virus was removed after 48 hours and cells were selected for ~5 days with Puromycin
Dihydrochloride (A1113803, Gibco) at 1 ug/mL for 293T cells and 3 ug/mL for BV-2 cells.
Protein isolation and western blot
Whole cell extracts were isolated using NP-40 Lysis Buffer (50 mM Tris, pH 7.4, 250 mM NaCl,
5 mM EDTA, 50 mM NaF, 1 mM Na3VO4, 1% Nonidet P40 (NP40), 0.02% NaN3) (Thermo
Fisher Scientific). Fifteen micrograms of the protein were separated on a 4-15% MiniPROTEAN TGX Precast Gel and transferred to PVDF membranes (Bio-rad). Membranes were
blocked with 5% milk in 1x Tris-Buffered Saline, 0.1% Tween or 2% bovine serum albumin
(BSA), incubated with the primary antibodies against KDM6A (D3Q1I, Cell Signaling) or Bactin (622102, BioLegend), washed three times with TBST, and incubated with anti-rabbit
horseradish peroxidase-conjugated secondary antibodies. Primary antibodies were used at a
concentration of 1:1000 and secondary antibodies were used at a concentration of 1:5000.
Membranes were developed with chemiluminescence on a ChemiDoc Imaging System (BioRad).
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RT- qPCR
1.0x106 cells were collected and lysed in 100 ul Direct-zol. Next, total RNA was extracted using
RNA MiniPrep Plus kit and eluted in 50 ul of DNase/RNase Free Water (Zymo Research). RNA
was reverse transcribed into cDNA using random hexamers and ImPROM-IITM Reverse
Transcriptase in a reaction mixture of 20ul. 10 ul of reaction mixture were later subjected to realtime PCR analysis performed with Power SYBR Green (Thermo Fisher) and run on
QuantStudio3 (Applied Biosystems). The thermal cycling conditions were composed of 50°C for
2 min followed by an initial denaturation step at 95°C for 10 min, 45 cycles at 95°C for 15
seconds, 60°C for 1 minute, and back to 95°C for 15 seconds. For the final melt curve stage,
samples were brought back down to 60°C for minute and back up to 95°C for 15 seconds. Data
plotted in bar graph is the relative abundance of mRNA normalized to B-actin. All calculations
for mRNA level of tested gene were done in excel and done in biological triplicates:
CT("#$%) = (

Ct '( *+,-,./ + Ct '( *+,-,./ + Ct '( *+,-,./
)
3

CT("#$%) = (

Ct 01 *+,-,./ + Ct 01 *+,-,./ + Ct 01 *+,-,./
)
3

CT("#$%) = (

Ct '( 23$-456 + Ct '( 23$-456 + Ct '( 23$-456
)
3

CT("#$%) = (

Ct 01 23$-456 + Ct 01 23$-456 + Ct 01 23$-456
)
3

∆CT(7+8,459+ 4: 23$-456) = (Ct '( − Ct "#$% '( 23$-456 )
∆CT(7+8,459+ 4: 23$-456) = (Ct 01 − Ct "#$% 01 23$-456 )
∆CT(7+8,459+ 4: '() = (Ct '( − Ct '( )
∆CT(7+8,459+ 4: '() = (Ct 01 − Ct '( )
∆∆CT = 23∆*(
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Gene-specific primer sequences were as follows CEACAM1a (mouse):
CCTCTATTCCAGGAAGTCTGGC (forward) and GTTCAGGACAGTGTATGCGACG
(reverse); B-actin (mouse): ACTGTCGAGTCGCGTCCA (forward) and
ATCCATGGCGAACTGGTGG (reverse) (Origene, Keck Oligo Synthesis Resource at Yale).
RESULTS
The first aim of this study was to assess whether Kdm6a is responsible in viral entry or
post-entry mechanisms. Given Kdm6a is identified as a histone modifier, if it were to regulate
viral entry, we hypothesized that Kdm6a, either directly or indirectly, transcriptionally regulates
Ceacam1a activity. We tested Ceacam1a mRNA levels in BV-2 WT and KO cell lines. We
isolated RNA from the cell samples and performed RT-qPCR using a primer pair that detects
Ceacam1a. Using reverse transcriptase, we created complementary DNA (cDNA) copies of the
RNA, and then performed qPCR with the cDNA. Expression in the two cell lines was
normalized to B-actin (Figure 2). Interestingly, BV-2 WT cells expressed relatively high
Ceacam1a mRNA levels compared to BV-2 KO cells. An unpaired t-test indicated that the
mRNA expression levels of BV-2 WT and KO cells are statistically different, with a p-value <
0.0001.

mRNA expression (ΔΔCT)

Ceacam1
1.5

WT
KO

1.0

0.5

0.0
WT

KO

Figure 2. BV-2 WT cells express higher Ceacam1a levels compared to BV-2
KO cells
Cells with Kdm6a demonstrate higher Ceacam1 activity compared to Kdm6a
knockout cells.
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The second objective was to investigate which domains of Kdm6a are important in
Ceacam1a expression or viral entry more generally. In order to transduce BV-2 KO cells with
different mutational constructs, we initially aimed to rescue Kdm6a deficient cells with WT
Kdm6a. Specifically, human KDM6A was a promising candidate to rescue mouse Kdm6a
phenotype because mouse and human KDM6A are 97% identical at the amino acid sequence
level. Both proteins are comprised of 1,401 amino acids and weigh approximately 154 kDA.8
Furthermore, using a human transcript of KDM6A can inform hypotheses about how the
function of this protein is conserved across different coronavirus infections.
BV-2 KO cells and 293Ts were transduced with two different vectors driven by a CMV
and MSCVmu promoter. After transduction and selection with Puromycin, proteins from the
293T a nd BV-2 transduced cell lines were subjected to Western blot analyses to visualize
expression of the introduced protein. Analysis indicates that there is no visible expression of
Kdm6a in the rescued cell samples transduced with lentiviral vector containing a CMV promoter
(Figure 3a.). However, the same lentiviral vector is effective in 293T cells (Figure 3b.)

Figure 3a and 3b. KDM6A overexpression observed in 293T cells but not in BV-2 cells using lentiviral
vector with CMV promoter
293Ts were transduced with the respective lentiviral vector as a positive control. Expression of Kdm6a in 293Ts
is seen in transiently transfected cells and in transduced cells. Endogenous expression of Kdm6a was not
detectable. Expression of Kdm6a in transduced BV-2 KO was not observed.
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To circumvent this challenge, we used a different lentiviral vector. This vector contains a
self-cleaving T2A peptide that links the gene of interest and an antibiotic resistance gene.
Western blot analysis demonstrates that Kdm6a is not expressed in either BV-2 KO or 293T cells
(Figure 4). As a positive control, cells were also transfected with pcDNA3.1 UTX in 293T cells
(Figure 4).

Figure 4a and 4b. No KDM6A overexpression seen in 293Ts and BV-2 KO cells using vector with T2A
peptide.
293Ts were transduced with the respective lentiviral vector as a positive control. Expression of Kdm6a in
293Ts is seen in transiently transfected cells but not in transduced cells. Endogenous expression of Kdm6a was
not detectable. Expression of Kdm6a in BV-2 WT and rescued cells was not observed.

DISCUSSION
In this study, we investigate the role of Kdm6a in MHV viral infection, a gene which
emerged from our recent CRISPR screen probing for genes required for SARS-CoV-2 infection.
We first sought to address whether Kdm6a is relevant in viral entry or post-entry mechanisms.
We compared Ceacam1a expression (one of the cellular receptors that regulates MHV entry) via
RT-qPCR in BV-2 WT and KO cells, which demonstrated reduced mRNA expression levels in
BV-2 KO cells compared to BV-2 WT cells. This data suggests that Kdm6a promotes Ceacam1a
levels. Histone demethylation generally alters the strength of interaction between histones and
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DNA. DNA, which is normally tightly wrapped in histones, is relaxed following demethylation,
thus opening those regions for possible transcription. While we do not know whether these
results are from direct or indirect interactions, we speculate that Kdm6a, either through direct
epigenetic regulation of Ceacam1a or through regulation of a regulatory transcription factor,
influences receptor expression, and in turn a cell’s viral susceptibility. Given its seemingly
conserved function in SARS lineage CoVs and now MHV, clarifying the role of Kdm6a in
regulating viral entry may help elucidate the pathogenicity of SARS-CoV-2 and inform new
methods of diagnosis and treatment.
In the future, we hope to identify transcriptional regulators for Ceacam1a. In support of
the viral entry hypothesis, there is evidence that transcriptional regulator, Sox9, upregulates
Ceacam1a.50 Sox9 is a protein that binds to particular parts of a DNA to regulate the activity of
other genes.50 It has been found to function in various tumors and viruses.49,59 Preliminary data
(not shown) demonstrates that Sox9 expression levels are significantly lower in Kdm6a knockout
cells. While previous studies report Sox9 directly and indirectly regulates Ceacam1a expression,
it is still unclear whether Kdm6a acts directly upstream of Sox9 or if there are other
transcriptional regulators at play in MHV.49, 50 To this end, a more generalized and global
approach (using either RNA-sequencing or ATAC-sequencing, comparing WT and KO cells)
may help identify putative regulators.
To follow-up with the observation of reduced Ceacam1a in KO cells, I plan to test for
Ceacam1a protein expression in BV-2 WT and KO cells via western blot. Though we would
expect to see higher Ceacam1a expression in BV-2 WT cells than in BV-2 KO cells, we cannot
assume changes at the mRNA level manifest at the protein level. Often times, there are posttranslational modifications involved that will result in low protein expression or none at all.30 I

18

would also like to confirm Kdm6a is involved in viral entry by infecting BV-2 WT and KO cells
with an MHV pseudovirus, a replication deficient virus that consists of an MHV spike protein
complexed with a VSV core that will express a luciferase reporter protein. A pseudovirus is a
useful virological tool because it acts as a vector by which the spike protein mediates viral
entry.29 Therefore, expression of the luciferase reporter protein is dependent upon the MHV
spike protein attaching to Ceacam1 and entering the host cell. If there is a higher readout of
luciferase activity in BV-2 WT cells than in BV-2 KO cells when infected with pseudovirus, then
this is further evidence that Kdm6a plays a role in viral entry. I also plan to explore the link
between Kdm6a and Ceacam1a by overexpressing Ceacam1a in BV-2 KO cells. If viral infection
can be rescued, this assay will further lend support towards Kdm6a’s part in regulating receptor
activity in MHV. I further plan to perform a chromatin immunoprecipitation sequencing (CHIPseq) experiment to further understand how Kmd6a might regulate Ceacam1a. This would address
whether Kdm6a is bound to either the promoter or gene body regions, and would suggest a more
direct interaction. Additionally, as mentioned above, an alternative would be to perform RNAsequencing in BV-2 WT and KO cell lines to look for transcription factors that might be
differentially expressed in these two states. Candidate transcription factors can be screened using
the above CHIP-seq experiment (to see which genes Kdm6a binds to and potentially regulates),
and further tested through overexpression and knockout experiments.
In order to affirm our data above is correct and support future mutational analysis, further
work is needed to complement BV-2 KO cells with WT Kdm6a. Knockout cell lines are a
valuable resource to observe the function of a gene by silencing that particular gene of interest.31
However, it is important to verify that experimental findings are a direct result of the knockout,
and not an artifact of single cell cloning.31 A rescue assay is a method in which the gene of
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interest’s phenotype is restored in the KO cell lines.31 If the knockout of Kdm6a did not create
any phenotypic drift, we would expect the rescued and WT constructs to have comparable
Ceacam1a expression levels. Alternatively, if we successfully complemented the KO line and
observed that Ceacam1a levels were low, then there are epigenetic variations that need to be
addressed.
We attempted to rescue the knockout Kdm6a phenotype through introduction of wildtype
Kdm6a. The first lentiviral vector contained Kdm6a with a CMV promoter, a strong promoter for
transgene expression. We noted strong Kdm6a expression in 293T cells that were transduced
with this vector. However, we did not observe strong expression in BV2 lines, possibly due to
CMV promoter insufficiency in murine cell lines.18 This could be a potential reason as to why no
expression was detected (Figure 4). If the CMV promoter is not accessible in murine cell lines, it
is not possible for the gene of interest to be expressed. To determine whether integration
occurred, I plan to perform a genomic PCR of viral elements in the transduced BV2 line. If a
PCR product is identified, then this would suggest promoter inactivity.
At the same time, we transduced BV-2 and 293T cells with a vector containing a murine
stem cell virus (MSCVmu) promoter and a T2A peptide. A T2A peptide is a self-cleaving
peptide that links two genes of interest to one promoter.32 One advantage of a vector having a
T2A peptide is that the gene of interest and the antibiotic gene are expressed at comparable
levels.19 This ensures that the cells that have survived after antibiotic selection are also
expressing Kdm6a. Even though we did not observe expression of Kdm6a in either cell type,
there are corrective steps that can be taken.
First, it would be beneficial to concentrate the lentivirus supernatant before adding it to
the cells. Concentrating lentiviral stocks increases lentivirus titer via ultracentrifugation.20
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Another solution is to transiently transfect BV-2 cells directly. Although glial cell transfection
efficiency is low with lipid-based reagents such as TransIT and Lipofectamine 2000, other
polymer-based transfection reagents like Viromer RED have higher efficiency.33 Lipid-based
transfection reagents create lipid complexes around the exogenous plasmid creating a positive
surface charge, which ultimately allows the complex to fuse with the negatively charged cell
membrane and enter the cell through endocytosis.34 Once inside the cell, the complex navigates
its way to the nucleus from the cytoplasm.34 Studies show reagents such as Lipofectamine have
low efficiency in BV-2 cells because the lipid complex obstructs the transfer of DNA from the
cytoplasm to the nucleus.33 However, Viromer RED is a polymer-based reagent that complexes
around the DNA. The complex is taken inside the cell in acidic endosomes and dissociates from
the DNA once in the cytosol.35 Viromer technology increases transfection in glial cells by 13%.33
Apart from using different transfection reagents, the manner in which the assay is carried
out can be changed. Reverse transfection is a technique where cells are transfected in suspension
and then directly added to the petri dish.36 In suspension, cells have greater surface area, thus
creating a higher chance of cell-to-DNA contact.36 This results in higher transfection
efficiency.36 One method specifically tailored to microglial cells is the transfection reagent,
Glial-Mag. Glial-Mag uses a magnetic force to drive the exogenous plasmid into the target
cells.37 Using a magnetic force ensures that cells come into contact with the nucleic acid.37 In
fact, Glial-Mag has higher transfection efficiency in BV-2 cells than any other chemical
transfection reagent.38 Nonetheless, directly transfecting BV-2 cells instead of using a lentivirus
system comes with its limitations. Transfection is transient, meaning the introduced plasmid only
stays in the cell for a limited amount of time.39 A lentivirus system, on the other hand, allows the
introduced plasmid to stay in the cell throughout multiple rounds of replication.39 If Kdm6a
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rescue remains unsuccessful or rescued cells were no longer susceptible to MHV infection, I
would consider using another cell line, rescuing mouse cells with murine Kdm6a, or employing a
different method to silence Kdm6a in BV-2 WT cells, such as Cas9-based homology directed
strategies.
When phenotypic rescue of Kdm6a is achieved, we will start investigating which domains of
Kdm6a are important in its viral functions. BV-2 WT and KO cells will be transduced with
different mutational constructs and later selected for with the appropriate antibiotic. A member
of the lab has constructed two mutations. The first construct contains two-point mutations,
H1146A and E1148A, in the JmjC domain. Though this results in a total loss of Kdm6a
demethylase activity, it does not change the expression of Kdm6a.25 This will reveal whether an
enzymatically inactive Kdm6a is capable of mediating viral entry. The second construct is a
G137V point mutation which results in decreased interaction between Kdm6a and other
methyltransferases. This hinders effective nuclear localization, a process required for effective
demethylation (Figure 5).24
The last two constructs are truncations that completely delete the TPR domain and the
JmjC domain. After these mutational constructs are introduced into BV-2 KO cells, a plaque
assay can be performed on all the Kdm6a complements. This will reveal whether the catalytic or
TPR domain of Kdm6a is responsible for viral infection. In the construct where the JmjC domain
is deleted, I would expect reduced viral infection. The active site of an enzyme is a region where
the substrate binds and chemical reactions take place.40 It also determines whether a protein is
functional.40 When an enzyme does not have a functional active site, it is rendered inactive and
can no longer perform its function (Figure 5).40
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Figure 5. Mutational constructs of Kdm6a
This figure demonstrates the type of mutational constructs that were made by a member of
the lab. Kdm6a is composed of two major domains: the TPR and JmjC domain. The first
construct contains two point mutations in the JmjC domain that renders the protein
catalytically inactive. The second construct contains one point mutation that results in
decreased interactions with other methyltransferases. The last two mutations are
truncations of the TPR domain or the JmjC domain.

Altogether, Kdm6a’s seemingly pan-coronaviral role stresses the importance of
uncovering the actions demethylases take in aiding viral infection. If a conserved mechanism is
discovered, it may be possible to use small molecule inhibitors to curb pathogenesis. GSK-J4 is a
common small molecule inhibitor that reduces demethylase activity in Kdm6a and other JmjC
domains.48 From our plaque assay results, lack of Kdm6a leads to a decrease in viral infection,
suggesting a role for such demethylase inhibitors.
CONCLUSION
In this study, we looked at the role KDM6A plays in viral entry and analyzed which
functional domains are pertinent to infection. Through RT-qPCR, we observed lower Ceacam1
levels in BV-2 KO cells compared to BV-2 WT cells. In order to interrogate Kdm6a’s role in
MHV infection further, we performed rescue assays. Our introductory data reveals Kdm6a
expression was not rescued using vectors with a CMV promoter or a vector containing a T2A
peptide due to the rigidity of the cell line and the overall difficulty of working with microglial
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cells. The ongoing study of Kdm6a’s demethylase activity in viral entry and infection is critical
for the development of therapeutics against coronaviruses, especially SARS-CoV-2. Although
progress has been made in understanding how Kdm6a might be acting, there is still a paucity of
data surrounding the precise mechanism. Thus, future work includes rescue experiments to
validate the phenotype seen in the RT-qPCR data and further characterizing the role of Kdm6a
towards this finding. In summary, our preliminary work herein provides useful information that
can help guide new experimental designs that elucidate Kdm6a’s role in MHV, and largely, in
other coronaviruses.
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